ClinicalTrials.gg
CompletedNCT06274177Updated Oct 16, 2024

Evaluation of the BTL-785F Device for Submental Fat Reduction and Neck Rejuvenation

An interventional study of BTL-785-7 in Fat Burn, sponsored by BTL Industries Ltd.. Completed at 4 sites in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by BTL Industries Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Jul 2023, registered Feb 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Study summary

This study will evaluate the clinical safety and the performance of the BTL-785F system equipped with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment.

Read the detailed description

This is a multi center single-arm, open-label, interventional study.

The subjects will be enrolled and assigned into one experimental study arm. The subjects will be required to complete four (4) treatment visits and two follow-up visits.

At baseline inclusion and exclusion criteria will be verified upon obtaining informed consent from the patient.

The treatment administration phase consists of four (4) treatment visits, delivered 5-10 days apart. Follow-ups visits at 1 month and 3 months after the final treatment will be held.

At every treatment visit after the first, prior to the procedure, the participants will be assessed for adverse effects resulting from the previous treatment(s) with the BTL-785F device.

Safety measures will include documentation of adverse events (AE) during and after the procedures and if needed medical assistance.

02

Conditions studied

  • Fat Burn

Keywords

  • submentum
  • neck rejuvenation
  • double chin
  • fat
03

In context

Lead sponsor

BTL Industries Ltd. is the lead sponsor of 77 studies on the registry; 5 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects over 21 years of age seeking treatment for reduction of submental fat
  • Subjects should be able understand the investigative nature of the treatment, the possible benefits and side effects, and must sign the Informed Consent Form
  • Presence of clearly visible excess fat in submentum as deemed appropriate by the Investigator
  • Subjects willing and able to abstain from partaking in any facial treatments other than the study procedure during study participation
  • Willingness to comply with study instructions, to return to the clinic for the required visits, and to have photographs of their face taken

Exclusion criteria

Exclusion Criteria:

  • Local bacterial or viral infection in the area to be treated
  • Local acute inflammation in the area to be treated
  • Impaired immune system caused by any immunosuppressive illness, disease or medication
  • Isotretinoin and tretinoin-containing medication use in the past 12 months
  • Skin related autoimmune diseases
  • Radiation therapy and/or chemotherapy
  • Poor healing and unhealed wounds in the treatment area
  • Metal implants
  • Permanent implant in the treated area
  • Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body
  • Facial dermabrasion, facial resurfacing, or deep chemical peeling in the treatment area within 3 months prior to the treatment
  • Current or history of skin cancer, or current condition of any other type of cancer, or pre-malignant moles
  • History of skin disorders, keloids, abnormal wound healing and dry or fragile skin
  • History of any type of cancer
  • Active collagen diseases
  • Cardiovascular diseases (such as vascular diseases, peripheral arterial disease, thrombophlebitis, hypersensitive carotid sinus and thrombosis)1
  • Pregnancy/nursing or IVF procedure
  • History of bleeding coagulopathies, use of anticoagulants
  • Any active condition in the treatment area, such as sores, psoriasis, eczema, rash and rosacea
  • Any surgical procedure in the treatment area within the last three months or before complete healing
  • Poorly controlled endocrine disorders, such as diabetes
  • Acute neuralgia and neuropathy
  • Kidney or liver failure
  • Nerve insensitivity (sensitivity disorders) to heat in the treatment area
  • Varicose veins, pronounced edemas1
  • Prior use of dermal fillers, botulinum toxin, lasers, etc. therapies in the treated area that can influence the study results at the investigator discretion
  • Unwillingness/inability to not change their usual cosmetics and especially not to use fat reduction, anti-aging or anti-wrinkles products in the treated area during the duration of the study including the follow-up period
  • Electroanalgesia without exact diagnosis of pain etiology
  • Neurological disorders (such as multiple cerebrospinal sclerosis, epilepsy)
  • Blood vessels and lymphatic vessels inflammation
  • Any other disease or condition at the investigator discretion that may pose risk to the patient or compromise the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    Treatment with BTL-785-7

    Treatment with BTL-785F device (BTL-785-7 applicator)

    Device: BTL-785-7

Interventions

  • DeviceBTL-785-7

    Treatment with the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat and skin laxity treatment

06

What researchers measure

Primary outcomes

  1. Submental fat thickness reduction

    The primary efficacy outcome measure is a statistically significant reduction of at least 1.0 mm in the average submental fat layer thickness in the majority of subjects measured by MRI at 3-months follow-up compared to baseline.

    Time frame: 15 months

Secondary outcomes

  1. Incidence of Treatment-related Adverse Events

    To evaluate the safety of the BTL-785F device with the BTL-785-7 applicator for non-invasive reduction of submental fat through monitoring of adverse reactions.

    Time frame: 15 months

  2. Change on the Clinician Reported - Submental Fat Rating Scale score

    Evaluation of the change in the Clinician Reported - Submental Fat Rating Scale (CR-SMFRS) grade. The scale ranges from grade 0 (no evident submental fat) to grade 4 (extreme submental convexity). Photographs from the last therapy, 1 month and 3 months follow-up will be compared to baseline photographs. An improvement is considered a decrease of the grade in the Clinician Reported - Submental Fat Rating Scale.

    Time frame: 15 months

  3. Satisfaction Assessed by the Satisfaction Questionnaire

    The 5-point Likert scale Subject Satisfaction Questionnaire will be used for evaluating the satisfaction. The Subject Satisfaction Questionnaire will be given to subjects after the last therapy, at 1-month and 3-month follow-up. The answers to the questions related to the subjects' under-chin and overall facial appearance will vary from "strongly agree" to "strongly disagree".

    Time frame: 15 months

  4. Change in the submental-cervical angle

    Statistically significant change in submental-cervical angle (SCA) convexity in the majority of the subjects

    Time frame: 15 months

  5. Comfort Assessed by Therapy Comfort Questionnaire

    The 5-point Likert scale Therapy Comfort questionnaire will be used for evaluating the comfort during the treatment sessions. Pain sensation will be rated by the subjects from 0 (no pain) to 10 (worst possible pain). The Therapy Comfort questionnaire will be given to subjects after the last therapy.

    Time frame: 15 months

07

Study locations

4 sites
  • Precision Skin LLC
    Davie, Florida 33328, United States
  • Chicago Cosmetic and Dermatologic Research
    Chicago, Illinois 60654, United States
  • New Jersey Plastic Surgery (NJPS)
    Montclair, New Jersey 07042, United States
  • Gentile Facial Plastic and Aesthetic Laser Center
    Youngstown, Ohio 44512, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Aug 2024, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2024
First posted
Feb 23, 2024
StartActual
Jul 26, 2023
Primary completionActual
Aug 4, 2024
CompletionActual
Sep 12, 2024
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06274177
Responsible party
Sponsor
First posted
Feb 23, 2024
Start date
Jul 26, 2023
Primary completion
Aug 4, 2024
Completion
Sep 12, 2024
Last update
Oct 16, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion